ReviewInternational journal of molecular sciences2017
Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 153 citations in OpenAlex.
- Cardiovascular-kidney-metabolic syndrome as a mitochondrial systems disorder.Nature reviews. Nephrology · 2026Review
- Sex-specific association between obesity and sympathetic nerve activity in HFpEF.American journal of physiology. Heart and circulatory physiology · 2026Article
- Salt and chronic kidney disease.Nature reviews. Nephrology · 2026Review
- Pre-existing anxiety and mood disorders and multisystem outcomes in young adults with chronic kidney disease.Clinical kidney journal · 2026Article
- Post-exercise heart rate recovery across stages of non-dialysis chronic kidney disease.Journal of human hypertension · 2026Observational
- Microparticles at the crossroads of the gut-kidney axis: Mechanistic drivers and therapeutic horizons in hemodialysis.World journal of nephrology · 2026Review
- Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial.ESC heart failure · 2026Article
- Neural Upregulation of SGLT2-MAP17-PDZK1 Complex in Kidneys of Rats With Heart Failure.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Management of Hypertension in Patients Undergoing Peritoneal Dialysis: A Narrative Review.Cureus · 2026Review
- Autonomic-vascular dysregulation in CKD-associated hypertension: a narrative review with evidence hierarchy.Frontiers in neuroscience · 2026Review
- Blood Pressure Management in Dialysis: A Comparative Review of Hemodialysis and Peritoneal Dialysis.Current hypertension reviews · 2026Review
- Structural brain changes, cerebral oxygenation, and cognitive function in hemodialysis patients: a cross-sectional study.Frontiers in medicine · 2026Article
- Inflammation in cardiovascular-kidney-metabolic syndrome: key roles and underlying mechanisms-a comprehensive review.Molecular and cellular biochemistry · 2025Review
- Cardiorenal Syndrome and Autonomic Overactivity.Biomedicines · 2025Review
- Cardio-Renal-Metabolic Syndrome with Emphasis on Chronic Kidney Disease: Educational Attainment and Progression-A Retrospective Cohort Study.Healthcare (Basel, Switzerland) · 2025Article
- Hidden Impacts of Peritoneal Dialysis on the Endocrine System.Life (Basel, Switzerland) · 2025Review
- Future perspective on chronic kidney disease management.Journal of anesthesia and translational medicine · 2025Review
- Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect.Biomedicines · 2025Review
- Safety and Efficacy of Renal Denervation for the Treatment of Resistant Hypertension in Patients with Chronic Kidney Disease: A Narrative Review of the Literature.Biomedicines · 2025Review
- Renal Denervation Improves Uremic Cardiomyopathy in Rats With Chronic Kidney Disease.Journal of the American Heart Association · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The incidence of chronic kidney disease (CKD) is increasing worldwide, with more than 26 million people suffering from CKD in the United States alone. More patients with CKD die of cardiovascular complications than progress to dialysis. Over 80% of CKD patients have hypertension, which is associated with increased risk of cardiovascular morbidity and mortality. Another common, perhaps underappreciated, feature of CKD is an overactive sympathetic nervous system. This elevation in sympathetic nerve activity (SNA) not only contributes to hypertension but also plays a detrimental role in the progression of CKD independent of any increase in blood pressure. Indeed, high SNA is associated with poor prognosis and increased cardiovascular morbidity and mortality independent of its effect on blood pressure. This brief review will discuss some of the consequences of sympathetic overactivity and highlight some of the potential pathways contributing to chronically elevated SNA in CKD. Mechanisms leading to chronic sympathoexcitation in CKD are complex, multifactorial and to date, not completely understood. Identification of the mechanisms and/or signals leading to sympathetic overactivity in CKD are crucial for development of effective therapeutic targets to reduce the increased cardiovascular risk in this patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.